Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sports Medicine: The New Playing Field

Executive Summary

Sports medicine is one segment of the device industry that may fare well in the post-health care reform world. New treatments aimed at preserving joint structures may protect young athletes from more invasive procedures down the road.

You may also be interested in...



Cartilage Repair: The Next Wave in Orthopedics

The musculoskeletal sector continues to be bogged down by the economic downturn, and particularly hard hit is the industry’s largest segment: the $13 billion total joint market. Companies are now scouting out the next technology wave in orthopedics, and the record attendance at the recent International Cartilage Repair Society meeting may be one indication of where the action will be for some time to come.

Bioactive Technologies for Bone Replacement

The global market for orthobiologics, comprised primarily of bone replacement materials, reached almost $2 billion in 2009 and is growing at an overall rate of 7%. Medtronic leads in bone replacement with a 45% market share, but overall growth in orthobiologics may come from emerging segments, particular synthetic and stem-cell based technologies.

Injectable Solutions for Joint and Back Pain

Injectable products that can alleviate pain and even reverse the disease process are on the horizon for treating degenerative orthopedic and spinal conditions, such as damaged articular joint cartilage and deteriorated spinal discs. With no available long-term treatment options for these conditions short of invasive surgical procedures like joint replacement or spinal fusion, injectable technologies that offer the possibility of being used upstream in the continuum of care are potential billion-dollar market opportunities. In fact, in a post health care reform environment, injectable therapies may prove to be the most cost-effective way for treating many degenerative conditions.

Related Content

Topics

Related Companies

Related Deals

Latest News
See All
UsernamePublicRestriction

Register

MT035392

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel